Anti-angiogenesis (anti-VEGF mAb)

Vascular endothelial growth factor (vascular endothelial cell growth factor, VEGF) is known to most strongly stimulate angiogenesis factor. Reduce or block the in vivo expression of VEGF, thereby preventing the VEGF-mediated angiogenesis can inhibit tumor growth and metastasis, or anti-inflammatory effect. Through independent research and development, we have successfully developed a plurality of anti-human vascular endothelial growth factor (VEGF) monoclonal antibody. One, code-named M23 monoclonal antibody and humanized antibody with a variety of human vascular endothelial growth factor (VEGF121, 165 and 189) highly specific binding, and can block VEGF binding to its receptor, and thus inhibit vascular endothelial the biological effects of cell proliferation and angiogenesis.

Angiogenesis or proliferation (angiogenesis) in biology refers to the body of existing blood vessels (such as capillaries and small arteries and veins) by budding or division manner to generate new blood vessels in the process. Angiogenesis in the maintenance of the body's many normal physiological processes such as embryonic development organizations, and other traumatic wound healing and repair is beneficial and necessary. However, excessive angiogenesis or proliferation but also with many pathological changes (such as proliferating tumor, inflammation, etc.) are closely related. The key to the body's blood vessels can continue its growth and proliferation of endothelial cells lining the ability to continuously divide proliferation and directed migration into existing vessel wall.